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Abstract 
Background: Ulcerative colitis (UC) is a chronic inflammatory gastrointestinal disease, notoriously challenging to 
treat. Previous studies have found a positive correlation between thymic atrophy and colitis severity. It was, 
therefore, worthwhile to investigate the effect of thymopentin (TP5), a synthetic pentapeptide corresponding to the 
active domain of the thymopoietin, on colitis.  
Methods: Dextran sulfate sodium (DSS)-induced colitis mice were treated with TP5 by subcutaneous injection. Body 
weight, colon length, colon weight, immune organ index, disease activity index (DAI) score, and the peripheral blood 
profile were examined. The immune cells of the spleen and colon were analyzed by flow cytometry. Histology was 
performed on isolated colon tissues for cytokine analysis. Bacterial DNA was extracted from mouse colonic feces to 
assess the intestinal microbiota. Intestinal lamina propria mononuclear cells (LPMCs), HCT116, CT26, and 
splenocytes were cultured and treated with TP5. 
Results: TP5 treatment increased the body weight and colon length, decreased the DAI score, and restored colon 
architecture of colitic mice. TP5 also decreased the infiltration of immune cells and expression levels of 
pro-inflammatory cytokines such as IL-6. Importantly, the damaged thymus and compromised lymphocytes in 
peripheral blood were significantly restored by TP5. Also, the production of IL-22, both in innate and adaptive 
lymphoid cells, was triggered by TP5. Given the critical role of IL-22 in mucosal host defense, we tested the effect of 
TP5 on mucus barrier and gut microbiota and found that the number of goblet cells and the level of Mucin-2 
expression were restored, and the composition of the gut microbiome was normalized after TP5 treatment. The 
critical role of IL-22 in the protective effect of TP5 on colitis was further confirmed by administering the anti-IL-22 
antibody (αIL-22), which completely abolished the effect of TP5. Furthermore, TP5 significantly increased the 
expression level of retinoic acid receptor-related orphan receptor γ (RORγt), a transcription factor for IL-22. 
Consistent with this, RORγt inhibitor abrogated the upregulation of IL-22 induced by TP5.  
Conclusion: TP5 exerts a protective effect on DSS-induced colitis by triggering the production of IL-22 in both 
innate and adaptive lymphocytes. This study delineates TP5 as an immunomodulator that may be a potential drug for 
the treatment of UC. 
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Introduction 
Ulcerative colitis (UC) is a chronic inflammatory 
gastrointestinal disorder most commonly afflicting 
adults aged 30-40 years impacting the quality of life 
[1, 2]. The incidence and prevalence of UC have 
increased worldwide with most cases reported in 









America [2]. However, UC has also been increasing in 
the East [3]. UC places a heavy burden on health-care 
systems; the annual direct and indirect costs related to 
UC are estimated to be as high as $8.1–14.9 billion in 
the USA [4]. As UC remains incurable so far, in the 
clinic, UC treatment has focused mainly on 
anti-inflammatory or immune-suppressing drugs, 
including 5-aminosalicylic acid, glucocorticosteroids, 
and immunosuppressants [5]. Despite their 
widespread use, there is little evidence to support the 
use of drugs such as glucocorticosteroids in UC. 
Moreover, although these treatments may reduce 
disease symptoms temporarily, they do not prevent 
future bouts of the disease and have a wide array of 
side effects [6]. New therapeutic strategies to treat UC 
are, therefore, urgently needed. Since UC is thought to 
be driven by a seemingly aberrant immune system 
attacking the gastrointestinal tract [7], immune- 
suppressive drugs are the mainstay of UC treatment. 
Although the topical colon presents with a 
hyperactive immune response, the pathology of UC is 
far more complicated than an abnormal immune 
response.  
Thymic atrophy is found in many kinds of colitis 
models, including a Gai2-/- colitis model [8, 9] and a 
dextran sulfate sodium (DSS)-induced colitis model 
[10]. Our recent results also showed a marked thymic 
involution in severe colitis [11]. Thymus, the primary 
lymphoid organ for T lymphocytes, is a common 
target organ that easily undergoes atrophy [12, 13]. 
Thymic atrophy caused by several endogenous and 
exogenous factors results in an impaired release of 
thymus-derived T cells and in impaired host 
immunity development and maturation. Considering 
the positive relationship between thymic atrophy and 
colitis severity [9], it is alarming that the widely used 
drugs for UC are immune-suppressive drugs, which 
are known to induce thymic atrophy and not much 
effort has been directed towards restoring or 
replacing thymic function in these diseases.  
Thymopentin (TP5), a synthetic pentapeptide 
corresponding to position 32-36 of thymopoietin, 
exhibits similar biological activity as thymopoietin 
responsible for phenotypic differentiation of T cells 
and the regulation of immune systems [14]. TP5 has 
been clinically used for the treatment of patients with 
immunodeficiency diseases, such as rheumatoid 
arthritis, cancers, hepatitis B virus infection, and 
acquired immunodeficiency syndrome (AIDS) [15, 
16]. Despite its extensive use in the clinic, the 
pharmacological effects and mechanisms action of 
TP5 have scarcely been studied in the past 10 years. 
Also, the possible effect of TP5 on colitis has not been 
investigated. Thus, the biological activity of TP5 on 
thymus prompted us to investigate its effect on colitis. 
Herein, we discovered that TP5 ameliorates 
DSS-induced colitis, accompanied by markedly 
increased lymphocyte fraction in peripheral blood. 
TP5 increased the expression of IL-22 and normalized 
the composition of gut flora which contributed to its 
therapeutic effect on colitis. Our findings highlight a 
new therapeutic strategy to restore UC.  
Results 
TP5 alleviated DSS-induced colitis 
The thymus can be considered as a barometer of 
health, readily undergoing atrophy in a variety of 
infectious diseases [12]. We observed thymic 
involution in DSS-induced colitis which was 
exacerbated as the severity of colitis progressed 
(Figure 1A), and thymus coefficient was negatively 
correlated to the disease activity index (DAI) score 
(Figure 1B). These results support the notion that 
promoting thymus restitution might be considered as 
a therapeutic approach for colitis. Remarkably, TP5, a 
synthetic alternative thymopoietin, dramatically 
blocked DSS-induced colitis, prevented the body 
weight loss, and increased the length of the colon and 
decreased the DAI score (Figure 1C-E). DSS-induced 
colitis was characterized by severe pathology 
throughout the proximal and distal colon, with 
extensive epithelial damage and inflammatory 
infiltrate. TP5 administration significantly decreased 
DSS-induced epithelial damage and inflammatory 
infiltrate and protected the integrity of the colon 
structure (Figure 1F). To monitor the effects of TP5 on 
the physiological functions in normal mice, we treated 
C57BL/6N mice with saline or TP5 for 7 days. TP5 
had no noticeable effect on mice including body 
weight, colon length, and histological structure of the 
colon (Figure S1A-C). The weight remained 
unchanged in mice treated with TP5 for 14 days 
(Figure S1D). Collectively, these results reveal that 
TP5 ameliorates the development of DSS-induced 
colitis.  
TP5 had no direct effect on colon epithelial 
cells 
The epithelial layer in the gastrointestinal tract 
represents the first line of defense against potential 
enteric pathogens. Epithelial regeneration is 
especially important for epithelial repair [17]. 
Consistent with the protective effect of TP5 on colitis, 
a significant increase in Ki-67 positive cells was 
observed in the colon of TP5-treated mice (Figure 2A). 
Intercellular junctions include the tight junctions, 
which contribute to the epithelial barrier [18]. TP5 
significantly increased the mRNA level of the tight 
junction protein 1 (Tjp1), but not mRNA levels of other 





tight junction proteins like Claudin-2 (Cldn2) and 
Occludin (Ocln) (Figure 2B). To examine whether TP5 
could directly promote the proliferation of epithelial 
cells, we treated two colon epithelial cell lines with 
TP5. Unlike the Ki-67 staining results in vivo, TP5 did 
not affect the proliferation of HCT116 or CT26 cells 
(Figure 2C). Also, no differences were found in Tjp1 
expression after TP5 treatment in either HCT116 or 
CT26 cells (Figure 2D). These results indicate that TP5 
has no direct effect on colon epithelial cells.  
 
 
Figure 1. TP5 alleviated DSS-induced colitis. (A) Thymus coefficient (thymus weight/body weight × 100) in colitis with different degrees of severity. (n=20-28). (B) Correlation 
between thymus coefficient and DAI score. (n=69). (C) Relative body weight of mice in each group after DSS treatment. (Relative body weight = body weight/average body weight 
in day 0 × 100) (n=10). (D) Representative colon pictures of each group. (E) Colon length, colon weight, and DAI scores in each group. (n=9-10). (F) Representative H&E staining, 
pathological scores of the proximal colon and distal colon in each group. The scale bar represents 100 μm. (n=4-5). * P < 0.05, ** P < 0.01, *** P < 0.001, compared with the 
normal group; # P < 0.05, ## P < 0.01, ### P < 0.001, compared with the DSS group. DAI: disease activity index; DSS: dextran sulfate sodium; TP5: thymopentin. Three 
independent experiments were performed. 






Figure 2. TP5 had no direct effect on colon epithelial cells. (A) Representative Ki-67 staining photographs, and mean positive Ki-67 cells counted in 20 crypts. The scale bar 
represents 50 μm. (n=4-5). (B) RT-PCR results of Tjp1, Cldn2, Ocln in mouse colons. (n=4-5). (C) Proliferation of TP5-treated HCT116 and CT26 cells. (n=6). (D) RT-PCR results 
for Tjp1 in HCT116 and CT26 cells. (n=6). * P < 0.05, ** P < 0.01, *** P < 0.001, compared with the normal group; # P < 0.05, ### P < 0.001, compared with the DSS group. Cldn2: 
claudin-2; DSS: dextran sulfate sodium; Ocln: occludin; Tjp1: tight junction protein 1; TP5: thymopentin. At least two independent experiments were performed. 
 
TP5 restored the number of peripheral 
lymphocytes 
Given the negative correlation between thymus 
coefficient and severity of colitis and the critical role 
of TP5 in the immune system, we set out to detect the 
effect of TP5 on circulating peripheral immune cells. 
We first analyzed the number and influx of circulating 
blood cells from the peripheral blood using an 
automated hematology analyzer (Siemens 
ADVIA2120i, Germany). DSS or TP5 treatment caused 
no significant changes in the number of circulating 
platelets (PLT), but TP5 significantly abrogated the 
downregulated number of red blood cells (RBC) 
induced by DSS, which is consistent with the 
protective effect of TP5 on colitic bleeding (Figure 
3A). Although no significant differences were found 
for the total white blood cells (WBC) in all groups, the 
subgroups of WBC were changed. DSS caused a 
significant increase in neutrophils (NEU)%, while TP5 
significantly decreased the proportion of NEU. 
Notably, the percentage of lymphocytes (LYM) was 
diminished in the DSS group, while TP5 significantly 
restored the percentage of LYM. TP5 also restored the 
percentages of eosinophils (EOS) and basophils 
(BASO). For monocytes (MONO)% and large 
unstained cell (LUC)%, no differences were found in 
all groups (Figure 3A). When mice were treated with 
saline or TP5 for 7 days, there were no differences in 
LYM%, NEU%, and MONO% (Figure S1E). However, 
the percentage of LYM was substantially increased in 
mice treated with TP5 for 14 days (Figure S1F).  
Thymus involution was observed in the DSS 
group, which was consistent with our previous study 
as well as those reported by others [11, 19]. As 
expected, TP5 significantly increased the thymus 
coefficient and saved the thymus from involution 
(Figure 3B). To examine whether TP5 alone could 
promote the enlargement of the thymus, we 
determined the thymus coefficient in TP5-treated 
mice. We observed that TP5 increased the thymus 
coefficient after 14 days of treatment but not in the 
mice treated for only 7 days (Figure S1G-H). It is 
possible that short-term use of TP5 has no apparent 
effect on the thymus, while long-term use can 
promote thymus regeneration in normal mice.  






Figure 3. TP5 restored circulating lymphocytes. (A) Blood examination of mice, including WBC, RBC, PLT, and percentage of NEU, LYM, MONO, EOS, BASO, and LUC. 
(n=4-5). (B) Thymus coefficient, spleen coefficient and lymph node coefficient in mice. (n=9-10). Organ (Thymus/spleen/lymph node) coefficient = Organ (Thymus/ spleen/lymph 
node) weight/body weight × 100. (C) Flow cytometry analysis of double positive (DP) cells (CD45+, CD4+, CD8+) in the thymus. (n=4-5). (D) Representative H&E staining 
photographs of the thymus in each group. The arrows showed the necrotic cells. The scale bar represents 50 μm. (n=4-5). (E) Flow cytometry analysis of T cells (CD45+, CD3e+) 
in the spleen. (n=4-5). * P < 0.05, ** P < 0.01, *** P < 0.001, compared with the normal group; # P < 0.05, ## P < 0.01 compared with the DSS group. BASO: basophil; DSS: dextran 
sulfate sodium; EOS: eosinophils; LUC: large unstained cell; LYM: lymphocyte; MONO: monocyte; NEU: neutrophil; PLT: platelet; RBC: red blood cell; TP5: thymopentin; WBC: 
white blood cell. At least two independent experiments were performed. 





We investigated the effect of TP5 on T 
lymphocytes in the thymus using flow cytometry 
(Figure S2A). The results showed a significant 
decrease in the percentage of immature double 
positive (DP) thymocytes in the DSS group and a 
significant increase after TP5 administration (Figure 
3C). The absolute number of total thymocytes were in 
line with the percentage of DP thymocytes (Figure 
S2B). Simultaneously, a substantial decrease of the 
CD4 single positive (SP) thymocytes and a slight 
decrease of the CD8 SP thymocytes were observed in 
the TP5-treated group compared with the DSS group 
(Figure S3B). As previously reported, thymic atrophy 
was found in DSS-induced colitis [10], and was 
accompanied with the cortical and medullary 
disorder in thymus [20]. In our study, the hematoxylin 
& eosin (H&E) staining of thymus indicated that DSS 
induced large intercellular space, cortical and medulla 
structure disorder and cell necrosis, while TP5 could 
alleviate the detrimental effects of DSS (Figure 3D). 
Also, the splenomegaly induced by DSS was reduced 
by TP5, though no significant differences were found 
in the lymph node coefficient (Figure 3B). 
Furthermore, TP5 had no effect on spleen coefficient 
of normal mice (Figure S1I-J). Similar to the results in 
blood, TP5 increased the percentage of LYM T and B 
cells in the spleen (Figure 3E and S2E). There were no 
significant changes in NEU%, NK cell%, or the 
composition of CD4 and CD8 LYM in the spleen 
(Figure S2D). All these results indicate that TP5 
restores the number of peripheral lymphocytes.  
TP5 diminished inflammation in the colon and 
increased IL-22 expression  
A hyperactive immune response in the colon is 
the hallmark of colitis. We, therefore, evaluated the 
effect of TP5 on inflammation-related cytokines and 
markers. Among the pro-inflammatory markers, DSS 
induced a significant increase of IL-6 mRNA and 
protein levels in the colon as previously described 
[21], while TP5 reversed the increased expression of 
IL-6 almost back to normal levels (Figure 4A and 
S3A). For IL-1β, IL-1α, TNF-α, and IL-18, TP5 had no 
apparent effect. However, TP5 significantly increased 
the mRNA and protein levels of IFN-γ, a cytotoxic 
cytokine promoting not only immunomodulation but 
also antimicrobial activity (Figure 4A and S3A). 
Infiltration of immune cells in the colon is a hallmark 
of UC. We observed an upsurge of chemokine CCL2 
and an influx of macrophages into the colon, both of 
which were significantly decreased by TP5 (Figure 
4A, 4B and S3B). Infiltration of T cells and NEU were 
also increased in the DSS group and compromised by 
TP5 (Figure S3C-D). 
Among some other cytokines, we identified a 
noticeable increase of IL-22 mRNA, and also a 
significant increase of IL-10 and IL-12 mRNAs in 
TP5-treated samples (Figure 4C). No differences were 
found in IL-23 and TGF-β mRNA expression. Protein 
levels of IL-22 were also substantially increased by 
TP5 not only in the colon but also in the blood (Figure 
4D). IL-22, a potent cytokine involved in tissue 
recovery and maintenance of barrier function, is 
mainly produced by T cells and group 3 innate 
lymphoid cells (ILC3s) [22, 23]. We first isolated the 
splenocytes and treated them with TP5 in vitro. 
Results showed a significant increase in the 
percentage of IL-22+ CD4+ T cells and increased 
expression of IL-22 mRNA (Figure 4E-F). Also, ILC3s 
of murine colon lamina propria mononuclear cells 
capable of producing IL-22 [17] were isolated and 
treated with TP5 in vitro. Results showed increased 
production of IL-22+ ILC3s (CD45+ CD4− RORγt+ 
IL-22+) in the TP5 group (Figure 4G). Besides, 
upregulation of IL-22 was observed in the thymus 
(Figure S3E) together with an increase of thymus 
coefficient in the group treated with TP5 for 14 days 
(Figure S1H). No differences in the IL-22 
concentration were found in the serum and colon 
(Figure S3E). The data from these observations 
emphasize that TP5 increases the expression of IL-22, 
which may protect mice from colitis.  
 
TP5 maintained mucus barrier and normalized 
gut microbiota 
Since IL-22 is primarily associated with the 
maintenance of mucus barrier function, we used 
Periodic Acid-Schiff (PAS) staining to assess the 
number of goblet cells which produce mucin. The 
results clearly showed restoration of the goblet cell 
number after TP5 treatment in colitic mice (Figure 
5A). Consistent with this observation, TP5 also 
significantly increased the expression levels of 
Mucin-2 (MUC2) mRNA, which is the building block 
of colonic mucus (Figure 5B).  
IL-22 is known to enhance the antibacterial 
defense of mucosal epithelial cells through different 
mechanisms [24], and UC is inextricably linked to the 
gut microbiome [25, 26]. Also, the expression level of 
the antibacterial protein lysozyme was increased by 
TP5 (Figure 5C). We, therefore, assessed the 
composition of the gut microbiota in the colonic feces 
of each group. TP5 maintained the homeostasis of gut 
microbiota, completely protecting them from DSS, as 
shown by principal component analysis (PCA) data 
(Figure 5D).  
 






Figure 4. TP5 diminished inflammation in the colon and increased IL-22 expression. (A) RT-PCR results of IL-6, IL-1β, IL-1α, TNF-α, IL-18, IFN-γ, and CCL-2 in colons of mice. 
(n=4-5). (B) Representative F4/80 staining photographs, and mean F4/80 positive cells counted in 5 fields. The scale bar represents 50 μm. (n=4-5). (C) RT-PCR results of IL-10, 
IL-22, IL-23, IL-12, and TGF-β in mouse colons. (n=4-5). (D) ELISA result of IL-22 in mouse colons and blood. (n=4-5). (E) Flow cytometry analysis of IL-22-producing splenocytes 
(CD45+, CD4+, IL-22+) treated with TP5 in vitro. (n=4). (F) RT-PCR results of IL-22 expression induced in splenocytes by TP5 in vitro. (n=4). (G) Flow cytometry analysis of 
IL-22-producing ILC3s (CD45+, CD4-, RORγt+, IL-22+) LPMCs treated with TP5 in vitro. (n=4). * P < 0.05, ** P < 0.01, *** P < 0.001, compared with the normal group/medium 
group; # P < 0.05, ## P < 0.01, ### P < 0.001, compared with the DSS group. DSS: dextran sulfate sodium; TP5: thymopentin. At least two independent experiments were 
performed. 






Figure 5. TP5 maintained the mucus barrier and normalized gut microbiota. (A) Representative PAS-stained goblet cell photographs and mean PAS+ goblet cells counted in 5 high 
power fields (HPF) in the colon. The scale bar represents 20 μm. (n=4-5). (B) RT-PCR results of MUC-2 in the colon. (n=4-5). (C) RT-PCR results of lysozyme in the colon. 
(n=4-5). (D) PCA of microbiota in colon content. (n=4). (E) Circus data showed the composition of microbiota in different groups at the phyla level. (n=4). (F) Data from bar plots 
showed the composition of microbiota in mice treated with saline, DSS and DSS+TP5 at the genus level. (n=4). * P < 0.05, *** P < 0.001, compared with the normal group; # P 
< 0.05, ### P < 0.001, compared with the DSS group. DSS: dextran sulfate sodium; MUC2: mucin-2; PAS: periodic acid-schiff; PCA: principal component analysis; TP5: 
thymopentin. 
The composition of microbiota at the phyla 
levels, as displayed in Figure 5E, indicates that the 
percentages of Verrucomicrobia, Bacteroidetes, and 
Actinobacteria were decreased sharply, whereas the 
percentages of Proteobacteria and Deferribacteres 
were increased in DSS-induced colitis. Consistent 
with the results of PCA, TP5 treatment abrogated the 
DSS-induced severe intestinal flora disturbance. To 
further confirm this result, we analyzed the 
composition of gut microbiota at the genus level. The 
results revealed that TP5 restored the greatly 
diminished composition of Akkermansia, Acinetobacter, 
Barnesiella, and Lactobacillus, and inhibited the 
markedly upregulated presence of Escherichia/Shigella, 
Bacteroides, Klebsiella, Staphylococcus, Enterococcus, and 
Clostridium sensu stricto in DSS-induced colitis (Figure 
5F). Collectively, these results indicate that TP5 
maintains the mucus barrier and normalizes gut 





microbiome, which may contribute to its protective 
effect on colitis.  
IL-22 mediated the protective effect of TP5 
To investigate whether the protective effect of 
TP5 was mediated by IL-22, we treated the 
DSS-treated mice with saline, TP5 and anti-IL-22 
antibody (αIL-22), and TP5 and isotype control 
antibody (Iso). Interestingly, the protective effect of 
TP5 was terminated by αIL-22, which also 
compromised the increased body weight and colon 
length in colitic mice treated with TP5 (Figure 6A-B). 
Also, αIL-22 abrogated the downregulation of DAI 
score in TP5-treated mice (Figure 6C). H&E staining 
revealed that αIL-22 blocked the protective effect of 
TP5 on colon inflammation and crypt damage of 
colitic mice (Figure 6E). Furthermore, in contrast to 
TP5+Iso, TP5+αIL-22 no longer upregulated LYM% or 
downregulated NEU% in the peripheral blood (Figure 
6D). These results confirm that IL-22 mediates the 
protective effect of TP5 in DSS-induced colitis. 
 
Figure 6. IL-22 mediated the protective effect of TP5 against DSS-induced colitis. (A-E) Mice were treated with DSS ± TP5 and given anti-IL-22 (αIL-22) or isotype control 
antibody (Iso) via i.p. once on day 0. (n=5). (A) Relative body weight curve of mice in each group. (B) Length of the colon and the representative colon photographs in each group. 
(C) DAI score. (D) Percentage of lymphocytes and neutrophils in whole blood. (E) Left: Representative H&E staining of proximal colon and distal colon. The scale bar represents 
50 μm. Right: Histological score. * P < 0.05, ** P < 0.01, *** P < 0.001, compared with the DSS group; # P < 0.05, ## P < 0.01, ### P < 0.001, compared with the DSS+TP5+Iso 
group. αIL-22: anti-IL-22 antibody; Iso: isotype control antibody; DAI: disease activity index; DSS: dextran sulfate sodium; LYM: lymphocyte; TP5: thymopentin. 





TP5 upregulated IL-22 through RORγt 
IL-22 can be produced by activated T cells and 
some subsets of innate lymphoid cells as previously 
described [24]. Also, transcription factors, such as 
Stat3, aryl hydrocarbon receptor (Ahr), RORγt, and 
nuclear factor of activated T cells (NF-AT), were 
reported to regulate IL-22 expression [27, 28]. To 
determine the mechanism of IL-22 expression 
promoted by TP5, we examined the regulatory factors 
of IL-22 in the colon samples from mice with or 
without treatment with TP5. We detected a 
significantly increased expression of RORγt in the 
DSS+TP5 group compared with DSS only group 
(Figure 7A). Similarly, we detected a higher number 
of CD45+ CD4- RORγt+ (ILC3s) and CD45+ CD4+ 
RORγt+ cells in the colon lamina propria mononuclear 
cells (LPMCs) in DSS+TP5 group than in the DSS only 
group (Figure 7B-C). Ursolic acid (UA), a RORγt 
inhibitor [29], prevented the production of IL-22 in 
spleen T cells induced by TP5 (Figure 7D). These 
results suggest that RORγt plays an important role in 
the upregulation of IL-22 following TP5 treatment.  
Discussion 
This study tried a new therapeutic strategy to 
combat UC, and found that TP5, a synthetic 
pentapeptide corresponding to the active site of 
thymopoietin, made a profound improvement on 
DSS-induced colitis. The immune-regulating reagent 
TP5 prevented thymic dysfunction in experimental 
colitis and restored the peripheral supply of 
lymphocytes. TP5 increased the expression level of 
IL-22, maintained the mucus barrier, and promoted 
normalization of the gut microbiota. Especially, TP5 
promoted the production of IL-22 in both innate and 
adaptive lymphoid cells in vitro. 
 
 
Figure 7. TP5 promoted IL-22 expression via RORγt. (A) RT-PCR results of stat3, Ahr, RORγt, and NF-AT in mouse colons. (n=4-5). (B-C) Flow cytometry analysis of ILC3s 
(CD45+, CD4-, RORγt+) and CD4+ RORγt+ cells (CD45+, CD4+, RORγt+) in colon LPMCs. (n=4-5). # P < 0.05, compared with the DSS group. (D) Flow cytometry analysis of 
IL-22 producing spleen T cells (CD45+, CD4+, IL-22+) treated with TP5 or ursolic acid (UA) in vitro. (n=6). At least two independent experiments were performed. * P < 0.05, 
compared with the medium group; # P < 0.05, compared with the TP5 group. DSS: dextran sulfate sodium; ILC3s: group 3 innate lymphoid cells; NF-AT: nuclear factor of 
activated T cells; TP5: thymopentin. 





Though UC is known as a chronic inflammatory 
disease affecting the colon, it is accompanied with 
thymic involution [11, 19, 30]. The thymus is known to 
be associated with colitis, as TgƐ26 transgenic mice 
[31] and T-cell receptor α chain-deficient mice [32] 
develop colitis. In our study, we found a negative 
correlation between thymus coefficient and DAI score 
in colitic mice. Thymic involution causes suppression 
of the immune system, thereby increasing the 
incidence and severity of infections. TP5 promotes the 
differentiation of thymocytes, restores 
cyclophosphamide-induced suppression of the 
immune system, and has been clinically used for the 
treatment of immunodeficiency diseases [33, 34]. 
Consistent with previous studies, we found that TP5 
significantly abolished the thymic involution induced 
by DSS and restored the proportion of lymphocytes in 
blood and spleen accompanied by the remission of 
colitis.  
Interestingly, although TP5 increased the 
proportion of peripheral lymphocytes, it decreased 
the percentage of inflammatory cells such as NEU in 
the peripheral blood. In the colon, the local 
inflammatory site, infiltration of macrophages and 
NEU were also decreased by TP5. Accordingly, 
pro-inflammatory cytokines, especially IL-6, were 
significantly diminished by TP5. The impaired 
inflammatory response was consistent with the 
protective effect of TP5 on the colon. These results 
negated concerns that immune enhancers like TP5 
might increase inflammation. Although 
immune-suppressive drugs are widely used in the 
clinic for the treatment of UC, it is generally believed 
that the benefit of immunosuppressants is likely to be 
small while the toxicity is high [35, 36]. On the other 
hand, immune-regulators such as TP5 might enhance 
the self-defensive ability of the body and thus 
mitigate the local inflammation of colitis.  
To determine the underlying molecular 
mechanisms of the protective effect of TP5 on colitis, 
we focused on cytokines produced by lymphocytes, 
which play a central role in cell proliferation and 
differentiation, and defense against pathogens. 
Among several protective cytokines, we observed a 
marked increase of IL-22 expression by TP5 in colon 
and blood. IL-22 is a member of the IL-10 cytokine 
family and has emerged in recent years as a key 
effector molecule in host defense and in the 
pathogenesis of autoimmune diseases such as colitis 
[24, 37]. The clinical relevance of IL-22/IL-22 receptor 
subunit 1 (IL-22R1) signaling system is being 
increasingly recognized in diseases such as psoriasis 
and UC [24]. The upregulation of IL-22 induced by 
TP5 is consistent with the idea that it may serve as a 
promising therapeutic agent for inflammatory bowel 
disease (IBD) [38]. Reports showed that IL-22 can be 
produced by activated T cells, including T helper 22 
(TH22) cells, TH17 cells, TH1 cells, as well as subsets of 
innate lymphoid cells [39-42]. To confirm the 
increased IL-22 induced by TP5 in vivo, we analyzed 
the production of IL-22 by TP5 in vitro. The results 
showed a significant increase in IL-22 expression in 
both innate and adaptive lymphoid cells. Most of 
these cells rely on specific transcription factors to 
promote the secretion of IL-22, for example, Stat3, 
Ahr, and RORγt [27]. Our results also indicated a 
critical role of RORγt in TP5-induced increase of 
IL-22. Notably, the abolishment of IL-22 completely 
blocked the protective effect of TP5 on colitis. The 
data emphasize that increased IL-22 by TP5 promotes 
recovery of mice from DSS-induced injury. 
Furthermore, IL-22 is reported to drive endogenous 
thymic regeneration [43], and TP5 alleviated 
DSS-induced thymic atrophy, thus thymus could 
supply more T cells to peripheral tissues to maintain 
immune homeostasis after TP5 treatment, forming a 
positive feedback loop. TP5, of course, is the effect on 
the thymus more important, or the direct effect on the 
lamina propria lymphocytes, needs to be further 
investigated by thymectomized mice or nude mice. 
We have demonstrated that TP5 protected colitis 
by producing IL-22 through RORγt/IL-22 signaling 
pathway, although how RORγt is induced by TP5 is 
not known. The receptor for TP5 has not yet been 
identified, and the downstream signaling pathway 
that directly interacts with TP5 is also not clear. It has 
been reported that T-cell receptor (TCR) [44] and 
Toll-like receptor (TLR2) [45] are the possible 
receptors of TP5. TP5 may bind directly to the 
membrane receptors on T cells and ILC3s to activate 
intracellular signaling pathways. We found that the 
expression level of Ahr in DSS+TP5 group was 
somewhat increased compared with the DSS group. 
Ahr is an important regulator in intestinal RORγt+ ILC 
and intraepithelial lymphocytes [46]. Interestingly, 
both Ahr and RORγt transcription factors could 
directly bind to the promoter of IL-22. Ahr expression 
alone only marginally increased IL-22 expression, 
while RORγt alone induced IL-22 transcription and 
strong synergism was observed in cell lines 
transduced with RORγt and Ahr [46]. Therefore, TP5 
may directly bind to the membrane receptors on T 
cells and ILC3s and stimulate the Ahr/RORγt/IL-22 
signaling pathway. Also, we found that the 
expression level of stat3 in DSS+TP5 group was 
higher than that in the DSS group. RORγt expression 
and TH17 differentiation are stat3-dependent [47], 
thus we speculated that TP5 may directly bind to the 
membrane receptors on T cells and ILC3s and activate 
the stat3/RORγt/IL-22 signaling pathway. However, 





how does TP5 actually regulate RORγt needs further 
investigation. We are trying to connect some reporters 
on TP5 and use some methods such as flow 
cytometry, Co-IP, mass spectrum etc. for further 
exploration. 
Target cells of IL-22 are found in organs that 
mainly constitute the outer-body barriers such as the 
gastrointestinal system, but not in organs 
orchestrating immunity. IL-22 is known to act on 
mucosal tissues to regulate host defense responses. 
Mucus and antibacterial protein play essential roles in 
preventing and limiting bacteria, and both can be 
induced by IL-22 [48, 49]. Therefore, the increase of 
IL-22 by TP5 may explain its remarkable effect in 
restoring the number of goblet cells and MUC2 
expression. The antibacterial protein lysozyme was 
also upregulated by TP5. It is of note that the 
markedly changed composition of the gut 
microbiome was abolished by TP5, which restored the 
composition of probiotics such as Lactobacillus and 
Akkermansia, known for its potential 
anti-inflammatory properties. Reduced levels of 
Akkermansia have been observed in patients with 
inflammatory bowel diseases (mainly UC) and 
metabolic disorders [50, 51]. TP5 also decreased the 
composition of some proinflammatory and harmful 
bacteria, such as Escherichia/Shigella, Bacteroides, 
Klebsiella, Staphylococcus, and Enterococcus. These 
promising results of TP5 on the gut microbiome 
makeup further confirmed the therapeutic effect of 
TP5 on colitis. However, the modulation of the gut 
microbiome is highly complex and needs further 
characterization.  
Collectively, our results showed that TP5 
increases the output of lymphocytes, elevates the 
expression of IL-22, normalizes the composition of the 
gut microbiome, and thus, alleviates DSS-induced 
colitis (Figure 8). Since thymus is a frequent target 
organ in a variety of diseases, this study not only 
posits an interesting concept that restoring an 
impaired thymus might be a useful therapeutic 
strategy for UC but also offers a therapeutic strategy 
for patients with the involuted thymus.  
Materials and Methods 
Mice. Male C57BL/6N mice aged 6-7 weeks 
were purchased from Charles River (Beijing, China). 
Mice were house-caged with a 12 h/12 h light/dark 
cycle and habituated in the room 3 days before 
experiments. Animal experiments were conducted 
according to the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals, with the 
approval of the Center for New Drug Safety 





Figure 8. A proposed model illustrating the therapeutic effect of TP5 on DSS-induced colitis. TP5 promotes RORγt expression and triggers the production of IL-22 in both T 
cells and ILC3s. IL-22 then enhances the mucosal host defense in colon maintaining the mucus barrier and normalizing gut microbiome. Furthermore, IL-22 promotes the 
regeneration of damaged thymus thus generating more IL-22-producing T cells forming a positive feedback loop. ILC3s: group 3 innate lymphoid cells; MUC2: mucin-2; TP5: 
thymopentin. 





Colitis induction with DSS. Colitis was induced 
by 2.5% DSS (36-50 kD, MP Biomedicals, Canada) in 
the drinking water for 7 days. TP5 (HAINAN 
ZHONGHE PHARMACEUTICAL CO., LTD., 
Hainan, China. No: 20170906, 20180402, 20 mg/kg) 
was administrated by subcutaneous (s.c.) injection 
once every day during the time schedule and mice 
were weighed daily. On day 8, as previously reported 
[52], mice were sacrificed, and the length and weight 
of the whole colon were recorded after opening 
longitudinally and flushing with PBS. DAI scores 
were determined as previously described [53, 54]. In 
brief, DAI was determined by scoring changes in 
weight, gross bleeding, and stool consistency. We 
used four grades of weight loss (0, no loss or weight 
gain; 1, 1% to 5% weight loss; 2, 5% to 15% weight 
loss; 3, more than 15% weight loss), four grades of 
stool consistency (0, normal; 1, slight loose; 2, loose; 
and 3, diarrhea), and four grades of gross bleeding (0, 
normal; 1, slight; 2, modest; and 3 severe). The 
combined scores constituted the final DAI. One-half 
of the mouse colons were used for flow cytometry 
analysis, and one half were divided into three sections 
(proximal, middle and distal). The proximal and distal 
colon sections were fixed in 4% phosphate-buffered 
formaldehyde for histological analyses. The middle 
colon was snap-frozen for subsequent molecular 
analyses. Mice treated with TP5 or saline for 7 or 14 
days were sacrificed on day 8 and day 15, 
respectively. For αIL-22 treatment, the mice were 
administrated with one intraperitoneal (i.p.) dose of 
400 µg anti-IL-22 (clone: IL22JOP, eBioscience, San 
Diego, USA) or 400 µg rat IgG2a κ isotype control 
(eBioscience, San Diego, USA), as previously 
described [55], and the mice were sacrificed on day 6 
as some mice were dying. 
Histology and immunohistochemistry. 
Proximal colon, distal colon, and the thymus tissues 
were fixed in 4% phosphate-buffered formaldehyde 
solution for 24 h and embedded in paraffin. Sections 
of 4 μm were stained with H&E. Colon inflammation 
and tissue damage were scored based on the degree of 
epithelial damage and inflammatory infiltrate in the 
mucosa, submucosa, and muscularis/serosa, as 
previously described [11, 56]. Each of the four scores 
was multiplied by 1 if the change was focal, 2 if it was 
patchy, and 3 if it was diffuse. The H&E sections of 
thymus were evaluated and graded for the structure 
disorder and necrosis in thymus using a 
semiquantitative scale from 0 to 3. Cortical and 
medullary disorders and lymphocytic necrosis were 
scored as follows: mild=1, moderate=2, and severe=3, 
and the sum of the two scores were the total 
pathological score. For immunohistochemistry, after 
dewaxing and rehydration, the colon sections were 
soaked in sodium citrate buffer for heat-induced 
epitope retrieval, and incubated with 10% goat serum 
for 1 h to block the nonspecific binding sites. 
Subsequently, sections were incubated with 
anti-F4/80 antibody (1:200, CST, USA) or anti-Ki-67 
antibody (1:100, CST, USA) overnight at 4℃, followed 
by incubation with horseradish peroxidase secondary 
antibodies for 20 min (MXB Biotechnologies, Fuzhou, 
China). The sections were stained using a 
Diaminobenzidine Substrate Kit (TIANGEN, Beijing, 
China) and counterstained with hematoxylin. Images 
were obtained with an Olympus BX41 microscope 
(Olympus, Japan). 
Cell isolation and flow cytometry. Colonic 
LPMCs were isolated following a previously 
established method [57]. In brief, luminal content, 
extraintestinal fat tissue, and blood vessels were 
removed, and colons were then cut into 0.5 cm pieces. 
The tissues were incubated in 20 mL of HBSS (Gibco, 
China) containing 5% FBS, 2 mM EDTA, and 1 mM 
DTT (Amresco, USA) at 37°C and predigested at 150 
rpm for 20 min. The colon pieces were minced with 
gentle MACSTM Octo Dissociator (Miltenyi Biotec, 
Germany) and digested in RPMI-1640 media 
(Biological Industries, Israel) containing 0.5 mg/mL 
Collagenase D (Roche, Mannheim, Germany), 0.5 
mg/mL DNase I (Sigma, USA), and 3 mg/mL 
Dispase II (Sigma, USA). The digested cell suspension 
was then washed with PBS and filtered through a 70 
μm cell strainer. Cells were stained with fluorescently 
conjugated antibodies: LIVE/DEAD™ fixable far-red 
dead cell stain kit (633 or 635 nm excitation, 
eBioscience, San Diego, USA), CD45 (BV510, Clone: 
30-F11, Biolegend, USA), CD45 (FITC, Clone: 30-F11, 
Biolegend, USA), CD11b (PE, Clone: M1/70, 
Biolegend, USA), Ly6G (PE-CY7, Clone: 1A8, 
Biolegend, USA), CD3e (PE, Clone: 1 45-2C11, BD 
Biosciences, San Diego, USA), RORγt (APC, Clone: 
B2D, eBioscience, San Diego, USA), and F4/80 (APC, 
Clone: BM8, eBioscience, San Diego, USA).  
Thymus homogenates or spleen homogenates 
after lysing red blood cells were also washed with PBS 
and filtered through the 70 μm cell strainer to get the 
cell suspension. Antibodies used for thymus staining 
included: LIVE/DEAD™ fixable violet dead cell stain 
kit (405 nm excitation, eBioscience, San Diego, USA), 
CD45 (FITC, Clone: 30-F11, Biolegend, USA), CD4 
(APC-CY7, Clone: GK1.5, Biolegend, USA), and CD8 
(PE-CY7, Clone: 53-6.7, Biolegend, USA). Antibodies 
used for spleen staining included: LIVE/DEAD™ 
fixable violet dead cell stain kit (405 nm excitation, 
eBioscience, San Diego, USA), CD45 (FITC, Clone: 
30-F11, Biolegend, USA), CD19 (APC, Clone: 6D5, 
Biolegend, USA), CD3e (PE, Clone: 145-2C11, BD 
Biosciences, San Diego, USA), CD4 (APC-CY7, Clone: 





GK1.5, Biolegend, USA), CD8 (PE-CY7, Clone: 53-6.7, 
Biolegend, USA), CD11b (PE, Clone: M1/70, Bio-
legend, USA), Ly6G (PE-CY7, Clone: 1A8, Biolegend, 
USA), NK1.1 (APC, Clone: PK136, Biolegend, USA), 
and F4/80 (APC, Clone: BM8, Biolegend, USA). Cells 
were analyzed with the Invitrogen™ Attune™ NxT 
Flow Cytometer (Invitrogen, USA) or BD 
FACSVerseTM Flow Cytometer (BD, USA) and were 
calculated using the FlowJo Software. 
For the experiments with colonic LPMCs in vitro, 
we isolated fresh colons from normal C57BL/6N mice 
and used the methods mentioned above to obtain 
sterile LPMCs, also as previously reported [58, 59]. 
The LPMC fractions were stimulated with TP5 (1 
μg/mL) and Brefeldin A (4 μg/mL, 
MedChemExpress, Monmouth, USA) in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS, 
Biological Industries, Israel), 1% glutmax (Gibco, 
100x, China), penicillin (100 U/mL, HyClone, USA), 
streptomycin (100 μg/mL, HyClone, USA) and 50 µM 
2-mercaptoethanol (Sigma, USA) for 12 h. For the 
experiments with splenocytes in vitro, we isolated 
fresh spleens from normal C57BL/6N mice. The 
tissues were ground and dispersed into single cells 
with a sterile cell strainer (Corning, Durham, USA). 
The cell suspension was then lysed with red blood cell 
Lysis buffer (ebioscience, San Diego, USA) for 5 min. 
The remaining cells were counted and cultured after 
washing, as reported before [58, 59]. The cells were 
cultured in the medium similar to LPMCs for 24 h 
except for Brefeldin A, and Brefeldin A was added for 
the last 4 h of culture. For some experiments, ursolic 
acid (2 μM, MedChemExpresss, Monmouth, USA), a 
RORγt inhibitor, was added to the spleen T cells. The 
cells were stained with the surface antibodies 
including LIVE/DEAD™ fixable far red dead cell 
stain kit (633 or 635 nm excitation, eBioscience, San 
Diego, USA), CD45 (BV510, Clone: 30-F11, Biolegend, 
USA), and CD4 (FITC, Clone: RM4-5, eBioscience, San 
Diego, USA), and were subsequently stained with 
RORγt (APC, Clone: B2D, eBioscience, San Diego, 
USA), IL-22 (PE, Clone: 1H8PWSR, eBioscience, San 
Diego, USA) after fixation and permeabilization 
(Cytofix/Cytoperm W/Golgi stop kit, BD Biosciences, 
San Diego, USA). Cells were detected by the BD 
FACSVerseTM Flow Cytometer (BD, USA) and were 
analyzed by FlowJo Software. 
Real-Time PCR analysis. Total RNA from colon 
tissues was extracted using RNeasy Plus Mini Kit 
(Qiagen, Germany), while cell cultures were extracted 
by using TRIzol (Invitrogen, San Diego, USA). 
Reverse transcriptase PCR (RT-PCR) was performed 
with a cDNA synthesis kit (Takara, China). 
Quantitative PCR was performed using SYBR Green 
QPCR Master Mix (Takara, China) with a Step one 
plus Real-Time PCR system (Applied Biosystems, 
USA). Relative amounts of mRNA were calculated by 
the ΔΔCt method with β-actin as house-keeping 
genes. For the primer sequences, some of them were 
from PrimerBank (https://pga.mgh.harvard.edu/ 
primerbank), others were designed with the Beacon 
Designer Software. All primers were custom-made by 
Genscript. The primer sequences were shown in 
Supplementary material. 
Inflammatory mediator measurement. Colon 
tissues were weighed and homogenized using a tissue 
mixer (PRO Scientific Inc., USA) with 15 volumes of 
PBS. The tissue samples were then centrifuged at 3000 
rpm for 20 min. Tissue supernatants were collected 
for the assays. IL-22 (Lianke Biotech CO., Ltd., 
Hangzhou, China), IL-1β, IFN-γ, TNF-α, and IL-6 
(Dakewe Biotech Co., Ltd., Shenzhen, China) 
concentrations were measured by ELISA.  
Immunostaining of goblet cells. For goblet cells 
immunostaining, tissue sections were dewaxed, 
hydrated, and stained with Periodic Acid-Schiff 
(PAS)/hematoxylin (SenBeiJia BioTech CO., Ltd., 
Nanjing, China). PAS+ goblet cells were counted in 5 
different areas of the section, and at least 10 sections 
of each mouse. Measurement and observation were 
performed with an Olympus BX41 microscope. 
16S rRNA sequencing and analysis. Colon 
content homogenates in PBS were immediately frozen 
(-80℃) and total community genomic DNA extraction 
was performed using an E.Z.N.A. Soil DNA Kit 
(Omega, USA), following the manufacturer’s 
instructions. Next-generation sequencing library 
preparations and Illumina MiSeq sequencing were 
conducted at Sangon Biotech (Shanghai, China). The 
16S rRNA V3-V4 amplicon was amplified using 
KAPA HiFi Hot Start Ready Mix (2×) (TaKaRa Bio 
Inc., Japan). Two universal bacterial 16S rRNA gene 
amplicon PCR primers (PAGE purified) were used: 
the amplicon forward PCR primer was 
5’-CCTACGGGNGGCWGCAG-3’ and the amplicon 
reverse PCR primer was 5’- GACTACHVGGGTATC 
TAATCC-3’. Sequencing was performed using the 
Illumina MiSeq system (Illumina MiSeq, USA), 
according to the manufacturer’s instructions. The 
effective sequences of each sample were submitted to 
the RDP Classifier to identify archaeal and bacterial 
sequences.  
Cell culture and TP5 administration. HCT116 
cells were cultured in McCoy's 5A medium (Biological 
Industries, Israel) including 10% FBS, 100 U/mL 
penicillin and 100 μg/mL streptomycin. The medium 
of CT26 cells was RPMI-1640 containing 10% FBS, 100 
U/mL penicillin and 100 μg/mL streptomycin. TP5 
(0.01, 0.1, 1 μg/mL) was administrated for 1 and 3 
days separately in the proliferation experiments, and 





1 day for the RT-PCR experiments. Cell proliferation 
was measured using sulforhodamine B (Sigma, USA) 
assay, as previously described [60]. 
Statistical Analysis. Data are presented as mean 
± SEM. Statistical significance was determined by 
two-tailed Student’s t-test between two groups, and 
one-way ANOVA followed by Dunnett’s posttests 
when groups were more than two. P < 0.05 was 
considered statistically significant.  
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